HUP9900730A3 - Solid mixtures of cyclodextrins prepared via melt-extrusion - Google Patents

Solid mixtures of cyclodextrins prepared via melt-extrusion

Info

Publication number
HUP9900730A3
HUP9900730A3 HU9900730A HUP9900730A HUP9900730A3 HU P9900730 A3 HUP9900730 A3 HU P9900730A3 HU 9900730 A HU9900730 A HU 9900730A HU P9900730 A HUP9900730 A HU P9900730A HU P9900730 A3 HUP9900730 A3 HU P9900730A3
Authority
HU
Hungary
Prior art keywords
extrusion
prepared via
solid mixtures
via melt
cyclodextrins prepared
Prior art date
Application number
HU9900730A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26139823&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP9900730(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of HUP9900730A2 publication Critical patent/HUP9900730A2/hu
Publication of HUP9900730A3 publication Critical patent/HUP9900730A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HU9900730A 1995-11-23 1996-11-20 Solid mixtures of cyclodextrins prepared via melt-extrusion HUP9900730A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95203219 1995-11-23
US09/081,808 US6365188B1 (en) 1995-11-23 1998-05-20 Solid mixtures of cyclodextrins prepared via meltextrusion

Publications (2)

Publication Number Publication Date
HUP9900730A2 HUP9900730A2 (hu) 1999-07-28
HUP9900730A3 true HUP9900730A3 (en) 2001-04-28

Family

ID=26139823

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9900730A HUP9900730A3 (en) 1995-11-23 1996-11-20 Solid mixtures of cyclodextrins prepared via melt-extrusion

Country Status (16)

Country Link
US (1) US6365188B1 (hu)
EP (1) EP0862463A1 (hu)
JP (1) JP3310299B2 (hu)
CN (1) CN1198655C (hu)
AU (1) AU725204B2 (hu)
BR (1) BR9611562A (hu)
CZ (1) CZ154398A3 (hu)
HU (1) HUP9900730A3 (hu)
IL (1) IL123654A (hu)
NO (1) NO981078L (hu)
NZ (1) NZ322907A (hu)
PL (1) PL189122B1 (hu)
SK (1) SK67298A3 (hu)
TR (1) TR199800729T2 (hu)
WO (1) WO1997018839A1 (hu)
ZA (1) ZA969831B (hu)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU725204B2 (en) * 1995-11-23 2000-10-05 Janssen Pharmaceutica N.V. Solid mixtures of cyclodextrins prepared via melt-extrusion
KR19990001564A (ko) * 1997-06-16 1999-01-15 유충식 용해도를 개선한 아졸계 항진균제 및 이를 함유하는 제제
CA2310847C (en) 1997-11-28 2007-03-13 Knoll Aktiengesellschaft Method for producing solvent-free non-crystalline biologically active substances
US6683100B2 (en) 1999-01-19 2004-01-27 Novartis Ag Organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
OA11674A (en) 1998-11-10 2005-01-12 Janssen Pharmaceutica Nv HIV Replication inhibiting pyrimidines.
US6194395B1 (en) 1999-02-25 2001-02-27 Orthro-Mcneil Pharmaceutical, Inc. Cyclodextrin cladribine formulations
DE19911097A1 (de) * 1999-03-12 2000-09-14 Basf Ag Verfahren zur Herstellung von festen cyclodextrinhaltigen Dosierungsformen
JP2003531099A (ja) 1999-03-24 2003-10-21 エフ エム シー コーポレーション 改良された水溶解度をもつ医薬製剤
BR0010279A (pt) 1999-05-04 2002-05-14 Janssen Phamaceutica N V éteres antifúngicos
FR2803748A1 (fr) * 2000-01-14 2001-07-20 Ethypharm Lab Prod Ethiques Composition d'itraconazole et procede de preparation
DE60136530D1 (de) 2000-03-01 2008-12-24 Janssen Pharmaceutica Nv 2,4-disubstituierte thiazolyl derivate
US6835717B2 (en) * 2000-03-08 2004-12-28 The Johns Hopkins University School Of Medicine β-cyclodextrin compositions, and use to prevent transmission of sexually transmitted diseases
WO2001085700A2 (en) 2000-05-08 2001-11-15 Janssen Pharmaceutica N.V. Hiv replication inhibiting pyrimidines and triazines
ITRN20000051A1 (it) 2000-12-22 2002-06-22 Ascor Chimici Srl Metodo e apparecchiatura per formare sferule composite contenenti principi attivi del tipo farmaceutico e/o integratori alimentari o cosmeti
GB0113841D0 (en) * 2001-06-07 2001-08-01 Boots Co Plc Therapeutic agents
EA007717B1 (ru) 2001-08-13 2006-12-29 Янссен Фармацевтика Н.В. 2-амино-4,5-тризамещенные производные тиазолила
US8101629B2 (en) 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
PL214279B1 (pl) 2002-03-13 2013-07-31 Janssen Pharmaceutica Nv Pochodna sulfonyloaminowa, sposób jej wytwarzania i zastosowanie oraz kompozycja farmaceutyczna i sposób jej wytwarzania
US7501417B2 (en) 2002-03-13 2009-03-10 Janssen Pharmaceutica, N.V. Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase
US7399856B2 (en) 2002-08-09 2008-07-15 Janssen Pharmaceutica N.V. Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-2pyrimidinyl]amino]benzonitrile
ATE402152T1 (de) 2003-02-07 2008-08-15 Janssen Pharmaceutica Nv Hiv-inhibierende1,2,4-triazine
CL2004000192A1 (es) 2003-02-07 2005-03-18 Janssen Pharmaceutica Nv Uso de compuestos derivados de 2-aminopirimidina para preparar un medicamento para la prevencion de una infeccion por vih relaciones sexuales o un contacto intimo en la pareja.
CL2004000303A1 (es) 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
EA009714B1 (ru) 2003-03-28 2008-02-28 Арес Трейдинг С.А. Препараты кладрибина для улучшенной пероральной доставки и доставки через слизистые оболочки
RS20050735A (en) * 2003-03-28 2008-06-05 Ares Trading S.A., Cladribine formulations for improved oral and transmucosal delivery
CN100475815C (zh) 2003-09-25 2009-04-08 詹森药业有限公司 抑制hiv复制的嘌呤衍生物
US20050118265A1 (en) * 2003-11-28 2005-06-02 Anandi Krishnan Antifungal oral dosage forms and the methods for preparation
KR101261305B1 (ko) 2004-07-28 2013-05-08 얀센 파마슈티카 엔.브이. 히스톤 디아세틸라제의 신규한 저해제로의 치환된 인돌릴알킬 아미노 유도체
CN101035773B (zh) 2004-08-10 2012-06-06 詹森药业有限公司 抑制hiv的1,2,4-三嗪-6-酮衍生物
ES2380631T3 (es) 2004-09-30 2012-05-17 Tibotec Pharmaceuticals Pirimidinas sustituidas en posición 5 inhibidoras de VIH
AU2005288864B2 (en) 2004-09-30 2012-08-23 Janssen Sciences Ireland Uc HIV inhibiting 5-heterocyclyl pyrimidines
ES2508766T3 (es) 2004-10-29 2014-10-16 Janssen R&D Ireland Derivados de pirimidina bicíclicos que inhiben el VIH
RU2403245C2 (ru) 2005-01-27 2010-11-10 Тиботек Фармасьютикалз Лтд. Ингибирующие вич производные 2-(4-цианофениламино)пиримидина
CN101133038B (zh) 2005-03-04 2012-06-27 泰博特克药品有限公司 抑制hiv的2-(4-氰基苯基)-6-羟氨基嘧啶
PT1912626T (pt) * 2005-08-08 2016-07-20 Abbvie Deutschland Formas farmacêuticas com biodisponibilidade melhorada
WO2007047253A2 (en) * 2005-10-11 2007-04-26 Eastman Chemical Company Pharmaceutical formulations of cyclodextrins and antifungal azole compounds
AU2007206942B2 (en) 2006-01-19 2012-08-23 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
EP1832281A1 (en) * 2006-03-10 2007-09-12 Abbott GmbH & Co. KG Process for producing a solid dispersion of an active ingredient
MX2008012577A (es) 2006-03-30 2008-10-10 Tibotec Pharm Ltd Pirimidinas sustituidas con 5-(hidroximetileno y aminometileno) que inhiben el virus de inmunodeficiencia humana.
EP2004632B1 (en) 2006-03-30 2014-03-12 Janssen R&D Ireland Hiv inhibiting 5-amido substituted pyrimidines
AU2007341228B2 (en) 2006-12-29 2013-04-18 Janssen Sciences Ireland Uc HIV inhibiting 5,6-substituted pyrimidines
KR20090094073A (ko) 2006-12-29 2009-09-03 티보텍 파마슈티칼즈 리미티드 Ｈｉｖ를 억제하는 6-치환된 피리미딘
EP2280681A1 (en) * 2008-04-30 2011-02-09 Novartis AG Continuous process for making pharmaceutical compositions
EP2427166B1 (en) 2009-05-07 2013-10-16 Gea Pharma Systems Limited Tablet production module and method for continuous production of tablets
US20120148678A1 (en) 2010-12-08 2012-06-14 Advanced Technologies And Regenerative Medicine, Llc. Sustained release of poorly water soluble active compounds
US10532102B2 (en) 2016-08-19 2020-01-14 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical composition and methods of uses
CN107441504A (zh) * 2017-09-06 2017-12-08 广州中医药大学 番茄红素包合物及其制备方法及番茄红素包合物片剂、胶囊和颗粒
CN110898015A (zh) * 2019-12-31 2020-03-24 上海汉维生物医药科技有限公司 一种伊曲康唑制剂的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61152765A (ja) * 1984-12-27 1986-07-11 Nippon Ekishiyou Kk シクロデキストリン類で包接された化合物を含有した合成樹脂製品及びその製造方法
US5009900A (en) * 1989-10-02 1991-04-23 Nabisco Brands, Inc. Glassy matrices containing volatile and/or labile components, and processes for preparation and use thereof
KR100291361B1 (ko) * 1992-10-14 2001-09-17 니뽄 신야쿠 가부시키가이샤 결정상태의전이방법
AU5376994A (en) * 1992-11-10 1994-06-08 Nippon Shinyaku Co. Ltd. Enclosure compound manufacturing method
FR2705677B1 (fr) * 1993-05-28 1995-08-11 Roquette Freres Micro-granules obtenus par extrusion-sphéronisation contenant une cyclodextrine.
AU725204B2 (en) * 1995-11-23 2000-10-05 Janssen Pharmaceutica N.V. Solid mixtures of cyclodextrins prepared via melt-extrusion
KR100331529B1 (ko) 1999-06-16 2002-04-06 민경윤 난용성 항진균제의 경구투여용 조성물 및 그의 제조 방법

Also Published As

Publication number Publication date
BR9611562A (pt) 1999-03-02
NZ322907A (en) 1998-12-23
PL189122B1 (pl) 2005-06-30
AU7694396A (en) 1997-06-11
NO981078L (no) 1998-05-22
IL123654A (en) 2001-08-08
IL123654A0 (en) 1998-10-30
ZA969831B (en) 1998-05-22
JPH11501050A (ja) 1999-01-26
EP0862463A1 (en) 1998-09-09
NO981078D0 (no) 1998-03-11
CZ154398A3 (cs) 1998-08-12
PL326161A1 (en) 1998-08-31
CN1198655C (zh) 2005-04-27
US6365188B1 (en) 2002-04-02
CN1200677A (zh) 1998-12-02
WO1997018839A1 (en) 1997-05-29
JP3310299B2 (ja) 2002-08-05
HUP9900730A2 (hu) 1999-07-28
AU725204B2 (en) 2000-10-05
SK67298A3 (en) 1998-11-04
TR199800729T2 (xx) 1998-07-21

Similar Documents

Publication Publication Date Title
NZ322907A (en) Solid mixtures of cyclodextrins prepared via melt-extrusion
PL322277A1 (en) Derivatives of pyrazol-4-ylobenzoyl
AU4006495A (en) Vibrating catheter
AU4844396A (en) Imidazoquinazoline derivatives
TW351994U (en) Diaper
EP0843984A4 (en) BIDET
EG21140A (en) Diaper
PL324451A1 (en) Derivatives of diphenylmethylenepiperidine
EP0747183A3 (en) Wood modification
AU7333096A (en) Crib
HUP9900506A3 (en) Prothrombin derivatives
HU9602433D0 (en) Cephalosporin derivatives
EP0727426A3 (en) Cephalosporin derivatives
GB9504336D0 (en) Diaper
AU4319997A (en) Deodorizing substance
EP0835478A4 (en) LED SOUND LAMP
AUPN728495A0 (en) Drier
GB9517570D0 (en) Mixtures
GB9521912D0 (en) Diaper
TW301373U (en) Improved structure of screw
ZA966266B (en) Cephalosporin fluoroquinolonate derivatives
GB9517723D0 (en) Use of molecular sieves
CA76358S (en) Bowl
CA76897S (en) Bowl
GB2297694B (en) Bowl